Haysam Akkad, MD
Interventional Cardiology · Omaha, NENPI 1013997741
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $9,362 of the $11,001 with a category attached, or 85.1%. Medtronic accounts for 94.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $8,611 and has fallen 99.3% since, to $60 in 2024.
Across 48 payments — averaging $229.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$10K
- Astellas Pharma US Inc$299
- Heartflow, Inc.$111
- Boston Scientific$93
- Itamar Medical Inc$28
- Lantheus Medical Imaging, Inc.$17
- plus $12 from 1 others
Across 24 payments — averaging $2168.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$40K
- Boehringer Ingelheim Pharma GmbH & Co.kg$12K
What the payments were for
- Travel & lodging$9,36285%
- Food & beverage$1,32812%
- Education$3113%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 39 | $10,441 |
| Astellas Pharma US Inc | 3 | $299 |
| Heartflow, Inc. | 1 | $111 |
| Boston Scientific | 2 | $93 |
| Itamar Medical Inc | 1 | $28 |
| Lantheus Medical Imaging, Inc. | 1 | $17 |
| Chiesi USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,001 in reported general payments places this provider in the 65th percentile of 50 interventional cardiology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,055 | $1,036,044 |
| XareltoRivaroxaban | 165 | $197,668 |
| EntrestoSacubitril/Valsartan | 74 | $80,657 |
| Metoprolol Succinate | 1,958 | $25,058 |
| BrilintaTicagrelor | 18 | $16,429 |
| JardianceEmpagliflozin | 15 | $16,008 |
| Dofetilide | 106 | $12,870 |
| Losartan Potassium | 793 | $6,619 |
| ClopidogrelClopidogrel Bisulfate | 647 | $5,804 |
| Flecainide Acetate | 107 | $4,562 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 580 | $4,530 |
| Metoprolol Tartrate | 818 | $4,364 |
| Torsemide | 220 | $4,357 |
| Atorvastatin Calcium | 591 | $4,280 |
| Amiodarone Hcl | 202 | $4,106 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Omaha
- Himanshu AgarwalOmaha$541K
- Poonam VelagapudiOmaha$142K
- Andrew GoldsweigOmaha$49K
- Jai ParekhOmaha$44K
- Scott CarolloOmaha$19K
- Shahbaz MalikOmaha$17K
- Toufik HaddadOmaha$14K
- Charles OlsonOmaha$12K
- Ajaypaul SukhiOmaha$9K
- Filip OleszakOmaha$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.